
"Obesity stigma is rising due to new weight-loss drugs" - Prof. Donal O'Shea
Brendan O'Connor
00:00
How much do patients pay and is public funding changing?
Donal details current costs for Ozempic and Mounjaro, limited public coverage, price strategies by companies, and potential HTA outcomes.
Play episode from 15:30
Transcript


